Four-peptide blend · never studied
KLOW mixes four peptides in one vial, and nobody has ever studied the mix. Whether you are curious, starting, or already using it, here is what is known, what is not, and what helps.

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.
Where are you with KLOW?
Good place to start. Here is what we would want to know before deciding, in plain words.
No study has tested KLOW. The closest one gave two of the four parts together to rats, and found no extra benefit over either part alone.
For TB-500 and KPV, the FDA found no data at all from people. BPC-157 has three small, poor-quality human studies, 30 people in all. GHK-Cu has small skin studies only.
None of the four parts is FDA approved. Law-firm summaries say the 2026 HHS draft policy covers single-ingredient products only and leaves out GHK-Cu, so a four-part vial falls outside it.
KLOW holds BPC-157 and TB-500. WADA bans both at all times.
Coming Pick your questions and print them as one page.
No judgement. Nobody has tested this combination in people, so there is no trial to say what to expect. Here is what still helps.
No study has tested KLOW in people, so there is no dose, schedule or cycle for it. Any dose question belongs with your doctor.
Labels differ between sellers: 80 mg, 90 mg or 40 mg in total, split in different ways. The amounts on a label are what is in the vial, not a dose. The calculator only turns those numbers into mg per mL.
If you mix a vial, use clean, careful technique. Nobody has published how long the mixed blend keeps or how to store it.
You’re using it. Nobody has tested this four-part mix in people, so keep a close eye on how you feel and keep your doctor in the loop.
If you get a rash or swelling, there is no way to tell which of the four parts caused it. And you cannot stop just one part while keeping the others.
For BPC-157, TB-500 and injected GHK-Cu, the FDA flags a possible immune reaction, meaning your body’s defences react to the peptide.
Notes like these help a doctor. They cannot tell you which part of the blend did what.
No judgement. We won’t tell you where to buy or how much to take, but these steps lower the risk whatever you use:
KLOW has no drug label, so there is no official list of warning signs for it. Here is what general allergy advice says, and when to call your doctor.
Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.
These are general signs of a severe allergic reaction, not a KLOW list. Call 911 or your local emergency number.
Bring the vial label, with the batch number.
No study has looked at stopping KLOW, so nobody knows what to expect. Talk it through with your doctor, and bring your notes.
Tell the FDA’s MedWatch about any bad reaction. Reports help spot problems with products nobody has studied.
Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.
No study has followed people taking KLOW, so there is no week-by-week picture from trials. Any KLOW timeline you see online has no study behind it.
One vial, four unknowns. If you feel better, you cannot tell which part helped. If you get a rash or swelling, you cannot tell which part caused it. And you cannot stop just one part while keeping the others.
Two parts together did no better in rats. In 32 rats with a repaired heel tendon, BPC-157 and TB-500 together gave no extra benefit over either one alone (animal study)[5].
Labels differ. The most common label we saw reads 80 mg in total, of which 50 mg is GHK-Cu. Others read 90 mg with no split, or 40 mg split evenly four ways. So two KLOW vials may not hold the same thing.
Storage is unknown. There is no label for KLOW. We found no published data on how long the mixed blend keeps or how to store it once mixed.
What is known about each part, in plain words:
No study of KLOW exists, so no one knows how often side effects happen. For TB-500 and KPV there are no human safety data at all. For BPC-157, TB-500 and injected GHK-Cu, FDA flags a possible immune reaction, meaning your body's defences react to the peptide[2].
KLOW and its parts have no drug label, so we do not make up a KLOW-specific list of warning signs. The general allergy signs in “Something feels off” at the top of this page come from MedlinePlus and apply to any product. If you feel unwell after any product, talk to a doctor or pharmacist and bring the vial label.
Notes like these help a doctor. They cannot tell you which part of the blend did what.
Any dose question belongs here. No KLOW dose has been studied, so there is no trial figure to point to.
What it is: a seller and forum name for a vial holding GHK-Cu, BPC-157, TB-500 and KPV. The blend itself has never been studied. Status: none of the four parts is FDA approved, and a four-ingredient vial is outside the HHS draft policy published 2026-10-30[8]. Evidence: blend, none; parts, from small human studies to cell only.
All human BPC-157 data in a 2026 systematic review, across 3 small studies[6]
Small human studyThe blend has no study at any level. Its parts range from small human studies (BPC-157, topical GHK-Cu) to animal only (TB-500) and cell and animal only (KPV).
Where the name comes from. On forums and seller pages, KLOW is read as "GLOW" (GHK-Cu, BPC-157 and TB-500) plus KPV. This is marketing usage. We found no developer, company, patent or first publication for the name.
What a typical vial label says. The most common seller label we saw (2026-11-17) reads 80 mg in total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. We do not link sellers.
Labels vary between sellers. Other labels we saw read 90 mg with no split given, or 40 mg split evenly four ways. Any arithmetic has to start from the numbers on your own label.
Sellers describe KLOW as being used for healing, skin and inflammation. The table shows how far the evidence for each part actually goes. None of it tests the blend.
| Part | What it is | Best human evidence | Study type | Page |
|---|---|---|---|---|
| BPC-157 | Synthetic 15-amino-acid peptide[10] | 3 small studies, n = 30 in total, judged very low certainty[6] | Small human study | Not yet on this site |
| TB-500 | Seven-amino-acid fragment of thymosin beta-4, LKKTETQ[2] | None: FDA found no human exposure data[2] | Animal | Not yet on this site |
| GHK-Cu | Copper-bound tripeptide[11] | Small topical trials; no injection study[12] | Small human study (topical only) | GHK-Cu |
| KPV | Tripeptide Lys-Pro-Val from alpha-MSH[13] | None: FDA found no human exposure data[2] | Cell and animal | KPV |
BPC-157. A 2026 systematic review found three small human studies with 30 people in total, all of poor quality[6]. They are a phone survey of 16 knee-pain patients at one clinic, 14 of whom reported relief, with no control group[14]; 12 women with interstitial cystitis given one 10 mg injection into the bladder wall, 10 of whom reported full resolution[15]; and a 2-person IV safety report[16].
TB-500 (not the same as thymosin beta-4). FDA has not identified any human exposure data for the TB-500 fragment[2]. A 2026 orthopaedic review stresses that TB-500 is a distinct short fragment with no proven equivalence to full-length thymosin beta-4[7]. The human trials of full-length thymosin beta-4, such as a 40-person IV phase 1[17], therefore say nothing direct about TB-500.
GHK-Cu. The human studies are small and topical, and some were negative. No study has tested injected GHK-Cu. See the GHK-Cu page for every trial.
KPV. KPV has been studied only in cells and animals, mainly mouse colitis models[18][13]. FDA found no human exposure data[2]. See the KPV page.
No. The closest study tested two of the four parts together in rats. In 32 rats with Achilles tendon repairs, BPC-157 and TB-500 given together brought no extra benefit over either one alone (animal study)[5]. There are no data on whether KLOW works or how long it might take.
None of the four parts is an FDA-approved drug, and no KLOW product is approved. Before April 2026 all four sat in FDA's category 2 of bulk substances that may present significant safety risks. FDA's reasons were possible immune reactions (BPC-157, TB-500, GHK-Cu), no human exposure data (KPV, TB-500) and limited human data (GHK-Cu)[2].
The HHS Secretary says about 14 peptides will be made more accessible.
Frier Levitt summary[19] RegulatorBPC-157, TB-500, KPV and injectable GHK-Cu leave FDA category 2 because their nominators withdrew them. Leaving the list does not make them legal to compound.
Frier Levitt summary of the FDA notice[19] RegulatorFDA's safety page lists all four parts under "nominated but withdrawn".
FDA safety-risk page[2] RegulatorFDA advisory committee votes 8-6-1 to recommend BPC-157, KPV and TB-500 for the 503A list. The vote is advisory; FDA staff had recommended against.
McDermott summary of the meeting[20] RegulatorHHS publishes a draft enforcement-discretion policy for compounding certain peptides. Law-firm summaries of its Appendix A list BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, as single-ingredient products only, with limited routes. GHK-Cu is not covered.
Federal Register 91 FR 68526; McDermott summary of Appendix A[8] RegulatorPlanned separate FDA advisory committee review of injectable GHK-Cu.
FDA 503A nominated substances list[21] RegulatorWhy a KLOW blend falls outside the 2026 HHS policy. The policy is a draft. According to law-firm summaries of its Appendix A, it covers only products with a single active ingredient, and it does not include GHK-Cu[22]. A four-peptide vial with GHK-Cu fails on both counts. We have not been able to read the appendix itself, and we will update this section if a final version is issued.
Research-use-only vials. Vials sold as "research use only" are not covered by any FDA list or by the HHS draft policy. We found no FDA warning letter or import alert naming KLOW (searched 2026-11-17).
Two of the four parts are named on the WADA Prohibited List[1]. A KLOW vial contains both.
| Part | WADA 2026 Prohibited List | Source |
|---|---|---|
| BPC-157 | Named under S0 (non-approved substances); banned at all times | WADA[1] |
| TB-500 | Named under S2.3 (thymosin beta-4 and its derivatives); banned at all times | WADA[1] |
| GHK-Cu | Not named; the S0 catch-all probably applies | WADA[1] |
| KPV | Not named; the S0 catch-all probably applies | WADA[1] |
| Part | Study | Amount as published | Route | How long | Study type |
|---|---|---|---|---|---|
| BPC-157 | Interstitial cystitis, n = 12[15] | 10 mg total, one procedure | Injection into bladder wall | Once | Small human study |
| BPC-157 | IV safety report, n = 2[16] | 10 mg day 1, 20 mg day 2 | IV | 2 days | Small human study |
| BPC-157 | Oral phase 1, no results posted[23] | 1, 3 or 6 mg single; 3 mg every 8 h; placebo | Oral tablet | Single dose or 2 weeks | Trial registry |
| TB-500 | No human dose published[2] | None | None | None | Regulator |
| Thymosin beta-4, full length (not TB-500) | Phase 1, n = 40[17] | 42, 140, 420 or 1260 mg daily vs placebo | IV | 14 days | Human RCT |
| GHK-Cu | No injected human dose published | None | None | None | None |
| GHK-Cu | Ongoing wound trial[24] | 0.1% gel once daily | Topical | 14 days | Trial registry |
| KPV | No human dose[2] | None | None | None | Regulator |
| BPC-157 + TB-500 | Rat Achilles repair, n = 32[5] | BPC-157 10 µg/kg/day; TB-500 60 µg/kg/day | Intraperitoneal | 4 weeks | Animal |
Not KLOW doses. Single-part studies only; animal amounts not converted.
Searches for a KLOW "dosage chart", "dose per day", "frequency" or "cycle" all have the same answer: none of these exists for the blend.
Your answer is saved only in this browser so you are not asked again. See the privacy policy.
Arithmetic only. Change the part sizes to match your own label; seller labels differ. For one peptide per vial, use the reconstitution calculator.
Adding water changes concentration, not the amount of peptide in the vial. For an 80 mg label split 50/10/10/10 mg (the common seller label described above):
| Water added | Total | GHK-Cu | BPC-157 | TB-500 | KPV |
|---|---|---|---|---|---|
| 2 mL | 40 mg/mL | 25 mg/mL | 5 mg/mL | 5 mg/mL | 5 mg/mL |
| 3 mL | 26.7 mg/mL | 16.7 mg/mL | 3.3 mg/mL | 3.3 mg/mL | 3.3 mg/mL |
Arithmetic from the label: mg in the vial divided by mL of water. Not a dose.
For the mixing steps, see how to reconstitute peptides and BAC water for peptides. We found no published stability data for the mixed blend, so there is no evidence on how long it keeps or how it should be stored once mixed.
| Part | What is known | Source | Study type |
|---|---|---|---|
| KLOW blend | No study, so no side-effect rates | PubMed and ClinicalTrials.gov search, 2026-11-17 | Trial registry |
| BPC-157 | No treatment-related adverse events reported in 30 people, but the studies were uncontrolled and poor quality, so this is not a safety finding | [6] | Small human study |
| TB-500 | No human safety data; FDA flags possible immune reactions from clumping | FDA[2] | Regulator |
| Thymosin beta-4, full length (not TB-500) | Adverse events "infrequent, and mild or moderate" in a 40-person IV phase 1 | [17] | Human RCT |
| GHK-Cu, injected | FDA flags possible immune reactions from clumping and impurities; limited human data | FDA[2] | Regulator |
| KPV | No human exposure data | FDA[2] | Regulator |
| Commercial products | Concerns about identity, purity, concentration and sterility | [7] | Review |
Reports online of swelling or "more inflammation" after starting KLOW have no published source, so we do not repeat them as findings.
| Name | GHK-Cu | BPC-157 | TB-500 | KPV |
|---|---|---|---|---|
| KLOW | Yes | Yes | Yes | Yes |
| GLOW | Yes | Yes | Yes | No |
| Wolverine | No | Yes | Yes | No |
Seller and forum names. None of these blends has been studied.
Separate vials vs one blend. No human study compares them. In rats, BPC-157 and TB-500 together gave no extra benefit over either alone[5]. Per law-firm summaries of the HHS draft policy, only single-ingredient products are covered, and GHK-Cu is not covered in any form[22].
There is no head-to-head data on KLOW against GHK-Cu alone. We found no interaction study of KLOW with retatrutide, naproxen, NAD or AOD-9604.
No trial of the blend is registered. These trials test single parts. The registry entries do not show doses for the first three, and three of the five share one sponsor whose background we have not checked.
| Trial | What it tests | Phase | Planned n | Status |
|---|---|---|---|---|
| [25] | BPC-157 vs placebo, hamstring strain | 2 | 120 | Recruiting |
| [26] | BPC-157 vs saline after rotator cuff repair | 1 | 30 | Not yet recruiting |
| [27] | TB-500 dose escalation, stable atherosclerosis | 1/2 | 80 | Recruiting |
| [24] | Topical 0.1% GHK-Cu gel, skin wounds | 2 | 60 | Recruiting |
| [23] | Oral BPC-157 safety, healthy volunteers | 1 | 42 | Unknown; no results posted |
Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.
Four peptides in one vial: GHK-Cu, BPC-157, TB-500 and KPV. The mix itself has never been studied.
Sellers market it for healing, skin and inflammation. No study has tested the blend. Some of its parts have never been tested in people at all.
Almost. GLOW is usually GHK-Cu, BPC-157 and TB-500. KLOW adds KPV. Neither blend has been studied.
No. None of its four parts is an approved drug, and no KLOW product is approved[2].
Not under the new draft rules. Law-firm summaries say the HHS draft from October 2026 covers only products with one active part, and leaves out GHK-Cu[22]. A four-part vial falls outside it.
KLOW holds BPC-157 and TB-500. WADA bans both at all times[1].
No one knows. No study has tested KLOW in people, so there is no dose, schedule or cycle for it. The dose table on this page lists what studies of single parts used.
There is no data. No study has tested KLOW or any of its parts with retatrutide.